PE20160079A1 - Nueva sal de la 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona, su preparacion, y las formulaciones que la contienen - Google Patents
Nueva sal de la 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona, su preparacion, y las formulaciones que la contienenInfo
- Publication number
- PE20160079A1 PE20160079A1 PE2015002679A PE2015002679A PE20160079A1 PE 20160079 A1 PE20160079 A1 PE 20160079A1 PE 2015002679 A PE2015002679 A PE 2015002679A PE 2015002679 A PE2015002679 A PE 2015002679A PE 20160079 A1 PE20160079 A1 PE 20160079A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- diona
- methylen
- thiazolidine
- pyrrol
- Prior art date
Links
- -1 4-MORPHOLINYLMETHYL Chemical class 0.000 title abstract 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000010586 diagram Methods 0.000 abstract 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE AL COMPUESTO METANOSULFONATO DE 3-[(3-{[4-(4-MORFOLINILMETIL)-1H-PIRROL-2-IL]METILEN}-2-OXO-2,3-DIHIDRO-1H-INDOL-5-IL)METIL]-1,3-TIAZOLIDINA-2,4-DIONA DE FORMULA (II) DONDE EL DOBLE ENLACE DE LA POSICION 3 DEL INDOL TIENE CONFIGURACION Z O E. DICHO COMPUESTO PRESENTA EN SU DIAGRAMA DE DIFRACCION X SOBRE POLVO LOS SIGUIENTES ANGULOS DE BRAGG 2 THETA: 12,86; 15,13; 15,50; 17,70; 18,25; 18,71; 20,11; 21,46; 21,67; 21,89; 22,29; 22,58; 24,57; 25,82 Y 26,33. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE CANCER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1356870A FR3008411B1 (fr) | 2013-07-12 | 2013-07-12 | Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20160079A1 true PE20160079A1 (es) | 2016-02-06 |
Family
ID=50424327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015002679A PE20160079A1 (es) | 2013-07-12 | 2014-07-11 | Nueva sal de la 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona, su preparacion, y las formulaciones que la contienen |
Country Status (47)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10245270B2 (en) * | 2013-07-12 | 2019-04-02 | Les Laboratoires Servier | Salt of 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, its preparation, and formulations containing it |
| FR3039401B1 (fr) * | 2015-07-31 | 2018-07-13 | Les Laboratoires Servier | Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR034118A1 (es) * | 2000-02-15 | 2004-02-04 | Sugen Inc | Compuestos de 2-indolinonas sustituidas con pirroles inhibidoras de proteinquinasas; sus composiciones farmaceuticas e intermediarios de sintesis |
| CA2424689A1 (en) * | 2000-10-17 | 2002-04-25 | Merck & Co., Inc. | Orally active salts with tyrosine kinase activity |
| AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| WO2003057690A1 (en) * | 2001-12-27 | 2003-07-17 | Theravance, Inc. | Indolinone derivatives useful as protein kinase inhibitors |
| US7105563B2 (en) * | 2003-10-24 | 2006-09-12 | Schering Aktiengesellschaft | Indolinone derivatives and their use in treating disease-states such as cancer |
| EP1959948B1 (en) * | 2005-12-05 | 2012-07-18 | XenoPort, Inc. | Levodopa prodrug mesylate, compositions thereof, and uses thereof |
| FR2948940B1 (fr) * | 2009-08-04 | 2011-07-22 | Servier Lab | Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2013
- 2013-07-12 FR FR1356870A patent/FR3008411B1/fr active Active
-
2014
- 2014-06-26 UY UY0001035629A patent/UY35629A/es unknown
- 2014-06-29 JO JOP/2014/0205A patent/JO3292B1/ar active
- 2014-07-11 TW TW105105577A patent/TW201630906A/zh unknown
- 2014-07-11 AU AU2014289059A patent/AU2014289059B2/en not_active Ceased
- 2014-07-11 RU RU2016104642A patent/RU2680826C9/ru not_active IP Right Cessation
- 2014-07-11 US US14/904,260 patent/US9925195B2/en not_active Expired - Fee Related
- 2014-07-11 EA EA201600101A patent/EA031526B1/ru not_active IP Right Cessation
- 2014-07-11 HK HK16110306.0A patent/HK1222172A1/zh unknown
- 2014-07-11 SG SG11201510570YA patent/SG11201510570YA/en unknown
- 2014-07-11 KR KR1020167003298A patent/KR20160030399A/ko not_active Ceased
- 2014-07-11 DK DK14758600.2T patent/DK3019497T3/en active
- 2014-07-11 UA UAA201600944A patent/UA114041C2/uk unknown
- 2014-07-11 MD MDA20160003A patent/MD4507C1/ro not_active IP Right Cessation
- 2014-07-11 MX MX2016000332A patent/MX360291B/es active IP Right Grant
- 2014-07-11 PT PT147586002T patent/PT3019497T/pt unknown
- 2014-07-11 HU HUE14758600A patent/HUE032568T2/hu unknown
- 2014-07-11 SI SI201430246A patent/SI3019497T1/sl unknown
- 2014-07-11 KR KR1020187006643A patent/KR20180028554A/ko not_active Ceased
- 2014-07-11 TN TN2015000566A patent/TN2015000566A1/fr unknown
- 2014-07-11 GE GEAP201414051A patent/GEP201706712B/en unknown
- 2014-07-11 WO PCT/FR2014/051783 patent/WO2015004395A1/fr not_active Ceased
- 2014-07-11 RS RS20170461A patent/RS55945B1/sr unknown
- 2014-07-11 ES ES14758600.2T patent/ES2632570T3/es active Active
- 2014-07-11 ME MEP-2017-149A patent/ME02735B/me unknown
- 2014-07-11 AP AP2016008976A patent/AP2016008976A0/xx unknown
- 2014-07-11 MA MA38759A patent/MA38759B1/fr unknown
- 2014-07-11 MY MYPI2016700018A patent/MY183197A/en unknown
- 2014-07-11 PL PL14758600T patent/PL3019497T3/pl unknown
- 2014-07-11 LT LTEP14758600.2T patent/LT3019497T/lt unknown
- 2014-07-11 TW TW103124019A patent/TWI554510B/zh not_active IP Right Cessation
- 2014-07-11 CN CN201480038854.7A patent/CN105377843B/zh not_active Expired - Fee Related
- 2014-07-11 NZ NZ715841A patent/NZ715841A/en not_active IP Right Cessation
- 2014-07-11 JP JP2016524879A patent/JP6532459B2/ja not_active Expired - Fee Related
- 2014-07-11 HR HRP20171060TT patent/HRP20171060T1/hr unknown
- 2014-07-11 EP EP14758600.2A patent/EP3019497B1/fr active Active
- 2014-07-11 PE PE2015002679A patent/PE20160079A1/es unknown
- 2014-07-11 AR ARP140102566A patent/AR096882A1/es unknown
- 2014-07-11 CA CA2916380A patent/CA2916380C/fr not_active Expired - Fee Related
-
2016
- 2016-01-04 PH PH12016500017A patent/PH12016500017B1/en unknown
- 2016-01-06 CL CL2016000013A patent/CL2016000013A1/es unknown
- 2016-01-07 CR CR20160012A patent/CR20160012A/es unknown
- 2016-01-07 DO DO2016000005A patent/DOP2016000005A/es unknown
- 2016-01-10 IL IL243526A patent/IL243526B/en not_active IP Right Cessation
- 2016-01-11 NI NI201600009A patent/NI201600009A/es unknown
- 2016-01-11 GT GT201600004A patent/GT201600004A/es unknown
- 2016-01-12 SA SA516370388A patent/SA516370388B1/ar unknown
- 2016-01-12 CU CUP2016000005A patent/CU20160005A7/es unknown
-
2017
- 2017-07-04 CY CY20171100714T patent/CY1119259T1/el unknown
-
2018
- 2018-02-14 US US15/896,273 patent/US20180207171A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124726T1 (el) | Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv | |
| CY1120703T1 (el) | Ετεροκυκλικες ενωσεις και χρησεις αυτων | |
| PH12019500188A1 (en) | Piperidine cxcr7 receptor modulators | |
| JO3425B1 (ar) | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b | |
| BR112016026291A2 (pt) | Derivados do ácido borônico e usos terapêuticos dos mesmos | |
| MX2020011449A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| PE20160605A1 (es) | Formulaciones de inhibidores de la syk | |
| CY1118379T1 (el) | Αναστολεις ιου ηπατιτιδας c | |
| MX2015008628A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MX2016005394A (es) | Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4. | |
| MX2021005052A (es) | Oxiesteroles y métodos de uso de los mismos. | |
| EA201201050A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| CU20160192A7 (es) | Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble | |
| EA201500821A1 (ru) | Производные 2-замещенных-6-биарилметиламино-9-циклопентил-9н-пуринов, их использование в качестве лекарственных средств и фармацевтических составов | |
| CO2018001700A2 (es) | Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos | |
| CR20160016A (es) | Pirazolpiridinas sustituidas | |
| AR095032A1 (es) | Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo | |
| ECSP16096831A (es) | Derivados de naftiridinadiona | |
| AR090073A1 (es) | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos | |
| MX2015012153A (es) | Inhibidores de la quinasa pirrolopirimidina cdk9. | |
| MX2016000884A (es) | Composicion para la gestion de las nauseas y los vomitos. | |
| UY34986A (es) | Derivados de diazepinona | |
| NI201600009A (es) | Nueva sal de la 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona, su preparación, y las formulaciones que la contienen | |
| ITUB20160650A1 (it) | Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione | |
| AR132461A2 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos |